Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 8-week, Dose Ranging, Open Label, Randomized, Phase 2 Study With a 44-week Extension, to Evaluate the Safety and Efficacy of MBX-8025 in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or Intolerance to Ursodeoxycholic Acid (UDCA)

NCT02955602 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02955602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02955602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 8-week, Dose Ranging, Open Label, Randomized, Phase 2 Study With a 44-week Extension, to Evaluate the Safety and Efficacy of MBX-8025 in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or Intolerance to Ursodeoxycholic Acid (UDCA)
Lead sponsor
Gilead Sciences
Phase
Phase 2
Overall status
Completed
Start date
November 28, 2016
Completion date
July 8, 2019
Enrollment
119 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

primary biliary cirrhosis